China Resources Double-Crane Pharmaceutical Co Ltd (600062) — Cash Flow-to-Debt Ratio
China Resources Double-Crane Pharmaceutical Co Ltd (600062) has a Cash Flow-to-Debt Ratio of 0.10x as of September 2025, meaning its operating cash flow of CN¥487.90 Million could theoretically repay 0% of its total liabilities (CN¥4.85 Billion) in one year. See 600062 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
China Resources Double-Crane Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (1998–2024)
Historical debt coverage capacity for China Resources Double-Crane Pharmaceutical Co Ltd across 27 annual periods. Also explore China Resources Double-Crane Pharmaceuti net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for China Resources Double-Crane Pharmaceutical Co Ltd (1998–2024)
Year-by-year debt coverage analysis for China Resources Double-Crane Pharmaceutical Co Ltd. For market capitalisation and broader financial context, see China Resources Double-Crane Pharmaceuti market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.33x | CN¥1.83 Billion | CN¥5.57 Billion | ▼ -27.8% |
| 2023 | 0.45x | CN¥1.65 Billion | CN¥3.64 Billion | ▲ +26.8% |
| 2022 | 0.36x | CN¥1.34 Billion | CN¥3.75 Billion | ▼ -14.7% |
| 2021 | 0.42x | CN¥1.34 Billion | CN¥3.20 Billion | ▼ -6.3% |
| 2020 | 0.45x | CN¥1.36 Billion | CN¥3.04 Billion | ▼ -19.2% |
| 2019 | 0.55x | CN¥1.44 Billion | CN¥2.60 Billion | ▼ -9.6% |
| 2018 | 0.61x | CN¥1.47 Billion | CN¥2.40 Billion | ▼ -18.0% |
| 2017 | 0.75x | CN¥1.19 Billion | CN¥1.59 Billion | ▲ +16.5% |
| 2016 | 0.64x | CN¥771.25 Million | CN¥1.20 Billion | ▲ +21.5% |
| 2015 | 0.53x | CN¥701.35 Million | CN¥1.33 Billion | ▼ -31.3% |
| 2014 | 0.77x | CN¥718.38 Million | CN¥934.93 Million | ▲ +61.0% |
| 2013 | 0.48x | CN¥546.24 Million | CN¥1.14 Billion | ▲ +117.0% |
| 2012 | 0.22x | CN¥396.05 Million | CN¥1.80 Billion | ▼ -25.5% |
| 2011 | 0.30x | CN¥511.53 Million | CN¥1.73 Billion | ▼ -25.9% |
| 2010 | 0.40x | CN¥509.67 Million | CN¥1.28 Billion | ▲ +37.7% |
| 2009 | 0.29x | CN¥342.01 Million | CN¥1.18 Billion | ▼ -2.4% |
| 2008 | 0.30x | CN¥331.71 Million | CN¥1.12 Billion | ▲ +64.8% |
| 2007 | 0.18x | CN¥235.46 Million | CN¥1.31 Billion | ▼ -25.1% |
| 2006 | 0.24x | CN¥303.71 Million | CN¥1.26 Billion | ▲ +222.1% |
| 2005 | 0.07x | CN¥139.78 Million | CN¥1.87 Billion | ▼ -62.2% |
| 2004 | 0.20x | CN¥453.72 Million | CN¥2.30 Billion | ▲ +236.9% |
| 2003 | 0.06x | CN¥148.94 Million | CN¥2.54 Billion | ▼ -16.2% |
| 2002 | 0.07x | CN¥140.63 Million | CN¥2.01 Billion | ▼ -37.7% |
| 2001 | 0.11x | CN¥141.01 Million | CN¥1.26 Billion | ▼ -59.2% |
| 2000 | 0.27x | CN¥172.81 Million | CN¥628.89 Million | ▼ -1.1% |
| 1999 | 0.28x | CN¥131.54 Million | CN¥473.60 Million | ▲ +502.2% |
| 1998 | -0.07x | CN¥-13.78 Million | CN¥199.57 Million | — |